PTC Therapeutics (PTCT) failed to convince a panel of FDA-appointed experts that its Duchenne muscular dystrophy drug Translarna was worthy of approval.

By a 10-1 vote, the FDA advisory panel concluded that while Translarna might be effective, the data submitted by PTC were inconclusive, and more work was needed to establish the drug’s efficacy. The sole dissenting vote to approve the drug now came from a panel member with a child with DMD.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy